A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus
Public ClinicalTrials.gov record NCT00482989. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI-545, a Fully Human Anti-Interferon-Alpha Monoclonal Antibody, in Patients With Systemic Lupus Erythematosus
Study identification
- NCT ID
- NCT00482989
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- MedImmune LLC
- Industry
- Enrollment
- 183 participants
Conditions and interventions
Conditions
Interventions
- MEDI 545 Biological
- Placebo Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2007
- Primary completion
- Jun 30, 2010
- Completion
- Aug 31, 2010
- Last update posted
- Jul 10, 2012
2007 – 2010
United States locations
- U.S. sites
- 18
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Anniston | Alabama | 36207 | — |
| Research Site | La Jolla | California | 92037-0943 | — |
| Research Site | Los Angeles | California | 90048 | — |
| Research Site | Clearwater | Florida | 37765 | — |
| Research Site | Fort Lauderdale | Florida | 33334 | — |
| Research Site | Ocala | Florida | 34474 | — |
| Research Site | Tampa | Florida | 33614 | — |
| Research Site | Shreveport | Louisiana | 71130 | — |
| Research Site | Baltimore | Maryland | 21205 | — |
| Research Site | Bethesda | Maryland | 20892 | — |
| Research Site | Manhasset | New York | 11030 | — |
| Research Site | New York | New York | 10003 | — |
| Research Site | New York | New York | 10021 | — |
| Research Site | Greenville | North Carolina | 27858 | — |
| Research Site | Oklahoma City | Oklahoma | — | — |
| Research Site | Portland | Oregon | 97223 | — |
| Research Site | Dallas | Texas | 75235 | — |
| Research Site | Dallas | Texas | 75390-8577 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00482989, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 10, 2012 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00482989 live on ClinicalTrials.gov.